116 related articles for article (PubMed ID: 10199933)
1. Examining the immune response in sentinel lymph nodes of mice and men.
Chu Y; Hu HM; Winter H; Wood WJ; Doran T; Lashley D; Bashey J; Schuster J; Wood J; Lowe BA; Vetto JT; Weinberg AD; Puri R; Smith JW; Urba WJ; Fox BA
Eur J Nucl Med; 1999 Apr; 26(4 Suppl):S50-3. PubMed ID: 10199933
[TBL] [Abstract][Full Text] [Related]
2. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
3. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast.
Kuerer HM; Peoples GE; Sahin AA; Murray JL; Singletary SE; Castilleja A; Hunt KK; Gershenson DM; Ioannides CG
J Interferon Cytokine Res; 2002 May; 22(5):583-92. PubMed ID: 12060497
[TBL] [Abstract][Full Text] [Related]
4. Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.
Meijer SL; Dols A; Hu HM; Chu Y; Romero P; Urba WJ; Fox BA
Cell Immunol; 2004 Feb; 227(2):93-102. PubMed ID: 15135291
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
[TBL] [Abstract][Full Text] [Related]
6. T Cells Derived From Human Melanoma Draining Lymph Nodes Mediate Melanoma-specific Antitumor Responses In Vitro and In Vivo in Human Melanoma Xenograft Model.
Zhang M; Graor H; Visioni A; Strohl M; Yan L; Caja K; Kim JA
J Immunother; 2015; 38(6):229-38. PubMed ID: 26049546
[TBL] [Abstract][Full Text] [Related]
7. Stages of the development of immunologic response in regional lymph nodes draining breast cancer.
Kozlowski H; Hrabowska M
Neoplasma; 1978; 25(4):445-52. PubMed ID: 308619
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
9. Melanoma exosomes enable tumor tolerance in lymph nodes.
Hood JL
Med Hypotheses; 2016 May; 90():11-3. PubMed ID: 27063077
[TBL] [Abstract][Full Text] [Related]
10. Experimental frontiers for clinical applications: novel approaches to understanding mechanisms of lymph node metastases in melanoma.
Essner R
Cancer Metastasis Rev; 2006 Jun; 25(2):257-67. PubMed ID: 16770538
[TBL] [Abstract][Full Text] [Related]
11. Nanostructured SL9-CpG Lipovaccines Elicit Immune Response for the Treatment of Melanoma.
Mu LM; Liu L; Liu R; Du YF; Luo Q; Xu JR; Xie Y; Lu WL
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31060324
[TBL] [Abstract][Full Text] [Related]
12. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
Hu HM; Urba WJ; Fox BA
J Immunol; 1998 Sep; 161(6):3033-41. PubMed ID: 9743368
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.
Slingluff CL; Yamshchikov GV; Hogan KT; Hibbitts SC; Petroni GR; Bissonette EA; Patterson JW; Neese PY; Grosh WW; Chianese-Bullock KA; Czarkowski A; Rehm PK; Parekh J
Ann Surg Oncol; 2008 Dec; 15(12):3538-49. PubMed ID: 18923873
[TBL] [Abstract][Full Text] [Related]
14. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes.
Faghih Z; Erfani N; Haghshenas MR; Safaei A; Talei AR; Ghaderi A
Immunol Lett; 2014; 158(1-2):57-65. PubMed ID: 24326038
[TBL] [Abstract][Full Text] [Related]
15. Regional lymphatic immunity in melanoma.
Grotz TE; Mansfield AS; Jakub JW; Markovic SN
Melanoma Res; 2012 Feb; 22(1):9-18. PubMed ID: 22082957
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene.
Chang AE; Sondak VK; Bishop DK; Nickoloff BJ; Mulligan RC; Mulé JJ
Hum Gene Ther; 1996 Apr; 7(6):773-92. PubMed ID: 9053030
[No Abstract] [Full Text] [Related]
17. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.
Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Teates D; Neese P; Grosh WW; Petroni G; Engelhard VH; Slingluff CL
Int J Cancer; 2001 Jun; 92(5):703-11. PubMed ID: 11340576
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
20. Memory CD4
Vahidi Y; Faghih Z; Talei AR; Doroudchi M; Ghaderi A
Cell Oncol (Dordr); 2018 Feb; 41(1):1-11. PubMed ID: 28994018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
